- GSK1904529A
-
- $34.00
-
2026-07-27
- CAS:1089283-49-7
- Purity: 99.96%
- Supply Ability: 10g
- GSK1904529A
-
- $1.10
-
2025-06-25
- CAS:1089283-49-7
- Min. Order: 1g
- Purity: 99.0% min
- Supply Ability: 100 tons min
|
| | GSK1904529A Basic information |
| Product Name: | GSK1904529A | | Synonyms: | CS-29;GSK1904529A;GSK-1904529A;GSK 1904529A;GSK 4529;GSK1904529A;GSK1904529A : IGF-IR, IGF-IIR inhibitor;N-(2,6-Difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamide;N-(2,6-difluorophenyl)-5-(3-(2-(5-ethyl-2-methoxy-4-(4-(4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)phenylamino)pyrimidin-4-yl)H-imidazo[1,2-a]pyridin-2-yl)-2-methoxybenzamide;N-(2,6-Difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamide GSK 1904529A | | CAS: | 1089283-49-7 | | MF: | C44H47F2N9O5S | | MW: | 851.96 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1089283-49-7.mol |  |
| | GSK1904529A Chemical Properties |
| density | 1.39 | | storage temp. | Store at -20°C | | solubility | ≥42.6 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O | | form | solid | | pka | 11.12±0.70(Predicted) | | color | Light yellow to yellow | | InChIKey | MOSKATHMXWSZTQ-UHFFFAOYSA-N | | SMILES | C(NC1=C(F)C=CC=C1F)(=O)C1=CC(C2=C(C3C=CN=C(NC4=CC(CC)=C(N5CCC(N6CCN(S(C)(=O)=O)CC6)CC5)C=C4OC)N=3)N3C(=N2)C=CC=C3)=CC=C1OC |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | GSK1904529A Usage And Synthesis |
| Uses | A selective inhibitor of IGF-1R and IR with IC50s of 27 nM and 25 nM, respectively. | | Uses | GSK 1904529A is a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. | | Definition | ChEBI: N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide is a member of benzamides. | | Biological Activity | gsk1904529a is a small-molecule inhibitor of the insulin-like growth factor-i receptor (igf-ir) with ic50 value of 27 nm 1.gsk1904529a is a reversible and atp-competitive inhibitor with ki value of 1.6 nm. in nih-3t3/lisn cells, gsk1904529a potently inhibited phosphorylation of igf-ir with ic50 value of 22 nm. it also demonstrated to be a selective inhibitor since it showed poor inhibitory activity against 45 other serine/threonine and tyrosine kinases. when treated with whole-cell extracts, gsk1904529a significantly inhibited the ligand-induced phosphorylation of igf-ir and decreased phosphorylation of downstream signaling including akt, irs-1 and erk at concentrations > 0.01μm. gsk1904529a suppressed cell proliferation in a variety of tumor cells. the ic50 values for nci-h929, tc-71, sk-n-mc, colo 205, mcf7 and prec are 81, 35, 43, 124, 137 and 68 nm, respectively. in colo 205, mcf-7, and nci-h929 cells, gsk1904529a treatment resulted in cell accumulation in g1 and decrease in s and g2-m phases. moreover, in nih-3t3/lisn xenograft model, once daily administration of gsk1904529a at 30 mg/kg inhibited 56% of tumor growth 1. | | in vivo | GSK1904529A (30 mg/kg; p.o. once or twice daily for 21 d) has antitumor activity in mice[1].
GSK1904529A (1-30 mg/kg; a single p.o.) decreases IGF-I-induced IGF-IR phosphorylation in a dose-dependent manner in mice[1].
GSK1904529A (30 mg/kg; p.o. once or twice daily for 21 d) has no significant alterations in the blood glucose levels in mice[1]. | Animal Model: | Female athymic nu/nu CD-1 mice are bring NIH-3T3/LISN tumor[1] | | Dosage: | 30 mg/kg | | Administration: | P.o. once or twice daily for 21 d | | Result: | Resulted in 56% (once daily) and 98% (twice daily) inhibition of tumor growth.
No significant decrease in body weight on the once-daily schedule.
Observed 11-13% of body weight loss, and recovered to near baseline 6 days after the cessation of treatment in twice-daily group.
|
| | target | IGF1R | | references | 1. sabbatini p, rowand j l, groy a, et al. antitumor activity of gsk1904529a, a small-molecule inhibitor of the insulin-like growth factor-i receptor tyrosine kinase. clinical cancer research, 2009, 15(9): 3058-3067. |
| | GSK1904529A Preparation Products And Raw materials |
|